Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6899467 | 0.79 | — | — | |
| SCHEMBL30802271 | 0.79 | APOBEC3G (0.36) | HTR7MAOAMAOB | |
| SCHEMBL29661845 | 0.79 | LMNA (0.39) | HTR7MAOAMAOB | |
| SCHEMBL944441 | 0.79 | APOBEC3G (0.36) | HTR7MAOAMAOB | |
| SCHEMBL8420683 | 0.79 | LMNA (0.39) | HTR7MAOAMAOB | |
| SCHEMBL355898 | 0.71 | — | — | |
| SCHEMBL9578982 | 0.70 | MAPT (0.44) | — | |
| Bromide SCHEMBL22686484 | 0.66 | ALDH1A1 (0.38) | — | |
| SCHEMBL18173493 | 0.66 | ALDH1A1 (0.38) | — | |
| SCHEMBL1043235 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868023-B2 | Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-11 | — | — | US | disclosed |
| EP-1863785-B1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-02 | — | — | EP | disclosed |
| US-20080255108-A1 | NOVEL THIOPHENE SULFOXIMINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | SUBASINGHE NALIN L | 2008-10-16 | — | — | US | disclosed |
| US-7385066-B2 | Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-10 | — | — | US | disclosed |
| EP-1863785-A1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING CMPLEMENT-MEDIATED DESEASES AND CONDITIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-12 | — | — | EP | disclosed |
| US-20070066667-A1 | Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| WO-2006101860-A1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255108-A1 | NOVEL THIOPHENE SULFOXIMINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | C5, C1R, C1QBP | HTR7 1822/4885MAOA 2287/4885MAOB 558/4885 |
| US-20070066667-A1 | Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions | C5, C1QBP, C1R | HTR7 1829/4885MAOA 2190/4885MAOB 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.